Literature DB >> 17452985

Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function.

M P Markey1, J Bergseid, E E Bosco, K Stengel, H Xu, C N Mayhew, S J Schwemberger, W A Braden, Y Jiang, G F Babcock, A G Jegga, B J Aronow, M F Reed, J Y J Wang, E S Knudsen.   

Abstract

Functional inactivation of the retinoblastoma tumor suppressor gene product (RB) is a common event in human cancers. Classically, RB functions to constrain cellular proliferation, and loss of RB is proposed to facilitate the hyperplastic proliferation associated with tumorigenesis. To understand the repertoire of regulatory processes governed by RB, two models of RB loss were utilized to perform microarray analysis. In murine embryonic fibroblasts harboring germline loss of RB, there was a striking deregulation of gene expression, wherein distinct biological pathways were altered. Specifically, genes involved in cell cycle control and classically associated with E2F-dependent gene regulation were upregulated via RB loss. In contrast, a program of gene expression associated with immune function and response to pathogens was significantly downregulated with the loss of RB. To determine the specific influence of RB loss during a defined period and without the possibility of developmental compensation as occurs in embryonic fibroblasts, a second system was employed wherein Rb was acutely knocked out in adult fibroblasts. This model confirmed the distinct regulation of cell cycle and immune modulatory genes through RB loss. Analyses of cis-elements supported the hypothesis that the majority of those genes upregulated with RB loss are regulated via the E2F family of transcription factors. In contrast, those genes whose expression was reduced with the loss of RB harbored different promoter elements. Consistent with these analyses, we found that disruption of E2F-binding function of RB was associated with the upregulation of gene expression. In contrast, cells harboring an RB mutant protein (RB-750F) that retains E2F-binding activity, but is specifically deficient in the association with LXCXE-containing proteins, failed to upregulate these same target genes. However, downregulation of genes involved in immune function was readily observed with disruption of the LXCXE-binding function of RB. Thus, these studies demonstrate that RB plays a significant role in both the positive and negative regulations of transcriptional programs and indicate that loss of RB has distinct biological effects related to both cell cycle control and immune function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452985     DOI: 10.1038/sj.onc.1210450

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

1.  Is hepatitis C virus carcinogenic?

Authors:  Stanley M Lemon; David R McGivern
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.

Authors:  Ankur Sharma; Wen-Shuz Yeow; Adam Ertel; Ilsa Coleman; Nigel Clegg; Chellappagounder Thangavel; Colm Morrissey; Xiaotun Zhang; Clay E S Comstock; Agnieszka K Witkiewicz; Leonard Gomella; Erik S Knudsen; Peter S Nelson; Karen E Knudsen
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 3.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

4.  Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control.

Authors:  Christopher A Reed; Christopher N Mayhew; A Kathleen McClendon; Erik S Knudsen
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

5.  Positive regulation of minichromosome maintenance gene expression, DNA replication, and cell transformation by a plant retinoblastoma gene.

Authors:  Paolo A Sabelli; George Hoerster; Lucina E Lizarraga; Sara W Brown; William J Gordon-Kamm; Brian A Larkins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

7.  Regulation of miR106b cluster through the RB pathway: mechanism and functional targets.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Adam Ertel; Meng Lim; Sankar Addya; Paolo Fortina; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 8.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

9.  Retinoblastoma protein (pRb), but not p107 or p130, is required for maintenance of enterocyte quiescence and differentiation in small intestine.

Authors:  Jun Guo; Shannon Longshore; Rajalakshmi Nair; Brad W Warner
Journal:  J Biol Chem       Date:  2008-11-03       Impact factor: 5.157

10.  RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1.

Authors:  C A Reed; C N Mayhew; A K McClendon; X Yang; A Witkiewicz; E S Knudsen
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.